Optimizerx CORP Form 4 insider transactions

Andrew J. D'Silva, Chief Business Officer of OptimizeRx Corp, reported a transaction in 1,432 shares of common stock on September 1, 2026.

Stephen L Silvestro, Chief Executive Officer of OptimizeRx Corp, received 79,200 shares of common stock on August 20, 2026.

Andrew J. D'Silva, Chief Business Officer of OptimizeRx Corp, received 57,600 shares of common stock on August 20, 2026.

Brendan W. Merrell, CHIEF OPERATING OFFICER of OptimizeRx Corp, received 57,600 shares of common stock on August 20, 2026.

Marion Odence-Ford, Chief Legal & Admin Officer of OptimizeRx Corp, received 57,600 shares of common stock on August 20, 2026.

Brendan W. Merrell, CHIEF OPERATING OFFICER of OptimizeRx Corp, reported a transaction in 1,020 shares of common stock on August 21, 2026.

Stephen L Silvestro, Chief Executive Officer of OptimizeRx Corp, reported a transaction in 1,737 shares of common stock on August 21, 2026.

Marion Odence-Ford, Chief Legal & Admin Officer of OptimizeRx Corp, reported a transaction in 1,529 shares of common stock on August 21, 2026.

Andrew J. D'Silva, Chief Business Officer of OptimizeRx Corp, reported a transaction in 1,243 shares of common stock on August 21, 2026.

Edward Stelmakh, Chief Finance & Strat Officer of OptimizeRx Corp, reported a transaction in 1,381 shares of common stock on August 21, 2026.

OptimizeRx Corp. reports that Director Cathy Klema acquired 34,517 shares of common stock on June 9, 2026, through a grant of restricted stock units.

OptimizeRx Corp director James Paul Lang acquired 34,517 shares of common stock through a restricted stock unit grant.

OptimizeRx Corp. reports a Form 4 filing detailing a director's acquisition of restricted stock units.

OptimizeRx Corp. reports a grant of restricted stock units to Director Patrick D. Spangler, vesting in one year or at the next annual meeting.

OptimizeRx Corp. reports a grant of restricted stock units to Director Ellen O'Connor Vos.

OptimizeRx Corp. reports that Director Gregory D. Wasson was granted restricted stock units (RSUs) on June 9, 2026, vesting on the earlier of the first anniversary of the grant or the company's next annual meeting.

OptimizeRx Corp reports a Form 4 filing detailing a director's acquisition of 13,060 shares of common stock.

OptimizeRx Corp's Chief Commercial Officer, Theresa Greco, reported a disposition of company shares on May 15, 2026, primarily to cover tax obligations upon the vesting of restricted stock units.

OptimizeRx Corp CEO Stephen L. Silvestro disposed of 5,219 shares of common stock to cover tax obligations upon the vesting of restricted stock units.

OptimizeRx's Chief Legal & Admin Officer, Marion Odence-Ford, acquired common stock through RSU conversion and sold shares to cover tax obligations.

OptimizeRx CEO Stephen L. Silvestro filed an amended Form 4 to clarify a stock disposition related to tax withholding on restricted stock units.

OptimizeRx Chief Commercial Officer Theresa Greco disposed of 1,420 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

OptimizeRx Corp's CEO, Stephen L. Silvestro, disposed of 3,361 common shares at $12.74 each to cover tax obligations from restricted stock unit vesting.

OptimizeRx's Chief Legal & Admin Officer, Marion Odence-Ford, reported a future disposition of 4,051 shares for tax withholding related to restricted stock unit vesting.

OptimizeRx's Chief Product & Tech Officer, Doug Besch, disposed of 4,079 common shares at $12.74 each to cover tax withholding obligations from RSU vesting.

OptimizeRx's Chief Finance & Strategy Officer, Edward Stelmakh, disposed of 3,658 shares of common stock at $12.74 per share to cover tax withholding obligations related to restricted stock unit vesting.

OptimizeRx's Chief Finance & Strategy Officer, Edward Stelmakh, filed an amended Form 4 to correct the transaction code for shares withheld for tax obligations.

OptimizeRx's Chief Finance & Strategy Officer, Edward Stelmakh, converted restricted stock units into common stock and subsequently sold a portion to cover tax obligations.

OptimizeRx CEO Stephen L. Silvestro reported the acquisition of common stock from RSU conversion and a related tax withholding disposition.

OptimizeRx's Chief Legal & Admin Officer, Marion Odence-Ford, acquired common stock through RSU vesting and subsequently sold shares to cover tax obligations.